|
 |
ActimmuneThis page contains recent news articles, when available, and an overview of Actimmune but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Throughout the call, we will refer to our commercial product, interferon gamma-1b, using its trade name, Actimmune, even when describing investigational ... Seeking Alpha (blog) InterMune Reports Third Quarter 2009 Financial Results and Business Highlights - Nov 5, 2009 Actimmune revenue totaled $19.6 million in the first nine months of 2009, compared with $23.3 million of Actimmune revenue in the first nine months of 2008, ... CNNMoney.com (press release) InterMune Inc. Reports Operating Results (10-Q) - Nov 6, 2009 The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other ... GuruFocus.com InterMune Q3 Loss Narrows; Updates FY09 Revenue Guidance - Quick Facts - Nov 5, 2009 ...(RTTNews) - InterMune Inc. (ITMN: News ) reported a third-quarter net loss of $8.771 million or $0.19 per share compared to a net loss of $13.982 million or ... RTT News How Hard Should It Be to Imprison Someone for Telling the Truth? - Oct 20, 2009 Th us, off -label use of Actimmune for IPF likely began shortly aft er the article was published in the New England Journal of Medicine. ... Linex Legal (registration) Hard Time For Biopharma CEOs (Part 2) - Oct 29, 2009 ...facing jail time after being convicted of wire fraud in a case involving claims that the company inappropriately promoted Actimmune via a press release. ... The IN VIVO Blog (blog) BUYINS.NET: JAZZ, ITMN, HSTX, PDC, CHINA, ELON Expected To Be Lower After ... - Nov 2, 2009 It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. ... TMC Net InterMune's loss widens in second quarter - Aug 6, 2009 The company's revenue came primarily from sales of Actimmune, an immune-system disorder drug. The company said the drop reflects lower off-label Forbes Ex-CEO in fraud trial over drug announcement - Aug 21, 2009 W. Scott Harkonen is under fire for a press release InterMune issued about the efficacy of its leading drug Actimmune, at a time when the company was trying FiercePharma InterMune Inc. Reports Operating Results (10-Q) - Aug 7, 2009 The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other GuruFocus.com Intermune (ITMN) Initiated Coverage Alert, Watch for 4.5 ... - Aug 12, 2009 Intermune (NASDAQ:ITMN) initiated with a Buy at Merriman. The stock closed yesterday at $14.28 on volume of 214900 Comtex Smartrend Bill & Melinda Gates Foundation Buys CSX Corp., M&T Bank Corp ... - Aug 27, 2009 The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other GuruFocus.com InterMune Posts Net Loss, Missing Estimates - Feb 27, 2009 InterMune's revenue fell 23.1% to $7.40 million from $9.63 million in the previous year's quarter, led by lower sales of Actimmune. TheStreet.com InterMune, Inc., Q4 2008 Earnings Call Transcript - Feb 26, 2009 We will refer to our commercial product, interferon gamma-1b, using its trade name, Actimmune, and we refer you to our website for complete prescribing Seeking Alpha InterMune slides, analysts focus on pipeline - Feb 27, 2009 Revenue fell to $7.4 million from $9.6 million, mainly on a 25 percent drop in sales of the immune-system disorder drug Actimmune. Forbes InterMune Stock Soars on Results of Lung Disease Drug Study - Feb 3, 2009 Its first drug candidate, Actimmune, had mixed results in a trial in 2002. Nevertheless, sales of the drug, which was already on the market for two rare New York Times, The Am Law Litigation Daily: December 10, 2008 - Dec 10, 2008 Former InterMune CEO Scott Harkonen, who is accused of illegally marketing the drug Actimmune, is facing a June 2009 trial. But his defense lawyers at The American Lawyer Carrier Won't Pay Former Biotech CEO's Legal Bills - Dec 8, 2008 Federal prosecutors accuse him of illegally marketing the company's drug Actimmune; the case will likely be the first of its kind to reach a jury. Law.com, InterMune Inc. - SWOT Analysis - companiesandmarkets.com adds new ... - Dec 8, 2008 The company currently markets Actimmune which is indicated for reducing the frequency and severity of serious infections associated with chronic Live-PR.com (Pressemitteilung), InterMune 3Q loss narrows on Roche payment - Nov 7, 2008 Sales of the immune-system disorder drug Actimmune fell 29 percent to $7.5 million. The company said the sales drop reflected lower off-label use of Forbes, InterMune Inc. - SWOT Analysis - companiesandmarkets.com adds new ... - Nov 18, 2008 The company currently markets Actimmune which is indicated for reducing the frequency and severity of serious infections associated with chronic PR-Inside.com (Pressemitteilung), InterMune Reports Third Quarter 2008 Financial Results and ... - Nov 7, 2008 Third quarter 2008 total revenue also included Actimmune(R) (interferon gamma-1b) revenue of $7.5 million, compared with $10.6 million of Actimmune revenue PharmaLive.com (press release), InterMune Reports Third Quarter 2008 Financial Results and ... - Nov 6, 2008 Third quarter 2008 total revenue also included Actimmune(R) (interferon gamma-1b) revenue of $7.5 million , compared with $10.6 million of Actimmune revenue Earthtimes (press release), InterMune Inc - Premium Company Profile - New Research Report on ... - Nov 14, 2008 The company markets Actimmune (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. Live-PR.com (Pressemitteilung), InterMune Reports Second Quarter 2008 Financial Results and ... - Jul 31, 2008 Total revenue in the second quarter of 2008 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.3 million, compared with $14.5 million CNNMoney.com (press release) InterMune Reports Second Quarter 2008 Financial Results and ... - Aug 1, 2008 Total revenue in the second quarter of 2008 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.3 million, compared with $14.5 million PharmaLive.com (press release), 2008-07-02 20:15:19 - www.companiesandmarkets.com adds new report ... - 02 Jul 2008 The company markets Actimmune (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. PR-Inside.com (Pressemitteilung), Rare Pulmonary Fibrosis may Have Blockbuster Potential - Jun 20, 2008 Currently, InterMune's Actimmune is prescribed off-label to treat IPF, though the off-label use has steadily declined in recent years in light of two BioWorld Online, InterMune IPF Treatment Receives Fast-Track Designation - May 27, 2008 InterMune’s previous president, Scott Harkonen, was indicted March 18 for alleged illegal marketing of Actimmune for IPF. The court has set a Sept. FDA news (subscription), Proteolix Appoints Thomas Kassberg Executive Vice President of ... - May 15, 2008 In this role, he oversaw the commercial team responsible for in-line sales of Actimmune(R) and pre-launch planning for late-stage products, Earthtimes (press release), Former drug company CEO indicted on wire fraud, FDCA charges - Apr 17, 2008 The indictment alleged that, under the CEO's direction, InterMune marketed and sold Actimmune® to treat idiopathic pulmonary fibrosis (IPF), a fatal disease CCH BeaconEquity.com – InterMune Inc. (ITMN) Shows Positive Trial ... - Apr 7, 2008 The company offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant oste (EMAILWIRE.COM, April 07, 2008 ) BeaconEquity.com Emailwire Barry M. Sherman MD to Write for Pharmservices - Mar 25, 2008 A list of the successful NDA’s (new drug approvals) that he has led includes Protropin, Nutropin, Activase, Actimmune, Pulmozyme, CD4IgG, Relaxin, gp120, PR.com (press release), Jean-Marie Eveillard Buys Legg Mason Inc., Verizon Communications ... - Feb 12, 2008 It offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. InterMune Inc. has a market cap of $625.58 GuruFocus.com, |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
